MVM V

VitalConnect is a company that specializes in wearable biosensor technology for wireless patient monitoring. It develops innovative solutions that enable continuous monitoring and recording of patients' vital signs through an adhesive patch applied to the body. The technology integrates expertise in biomedical engineering, data analytics, and chip design, allowing vital data to be displayed on mobile devices and computer systems. This capability empowers healthcare professionals to respond promptly to urgent situations and gain valuable insights into patient health, facilitating informed decision-making in both inpatient and outpatient settings, including hospital monitoring, post-discharge care, and cardiac monitoring.

GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, dedicated to improving the lives of patients with brain tumors. Founded in 2017, the company has developed an innovative treatment approach through its flagship product, GammaTile, which combines a biocompatible, conformable collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a bioresorbable solution that enhances treatment efficacy. GammaTile is protected by multiple patents and has the potential to benefit a significant patient population, with an estimated 176,000 patients diagnosed annually in the United States. To date, clinical trials at Barrow Neurological Institute have demonstrated promising outcomes, with significant clinical improvements observed in patients treated with this novel device.

OSSIO is an orthopedic fixation company established in 2014, dedicated to revolutionizing the orthopedic market by offering a non-permanent alternative to traditional metal implants. The company's flagship product, OSSIOfiber™, is a biocomposite material platform that combines reinforcing mineral fibers with intelligent bone regeneration technology. This innovative solution enables patients' bodies to regrow bone and recover from orthopedic disorders while minimizing inflammation and weakness often associated with other bio-resorbable materials. OSSIO aims to transform the $10 billion+ orthopedic fixation market by providing a more biologically friendly option for both patients and physicians.

Icotec specializes in the development and production of carbon fiber reinforced plastic implants for spine surgeries and accident treatments. The company focuses on creating innovative, highly stable implants for the operative treatment of spinal tumors, aiming to enhance the quality of life for patients by improving treatment options.

Nalu Medical is an early-stage company based in Carlsbad, California, focused on developing innovative medical devices to enhance the treatment of chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator that is cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS). Nalu Medical's neurostimulation devices leverage neuromodulation technology to offer a variety of therapeutic options aimed at alleviating chronic pain, thereby improving the quality of life for patients.

Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.

BioProtect Ltd. is an international medical device startup founded in 2004 and headquartered in Israel, with subsidiaries in Germany and the United States. The company specializes in the development and commercialization of biodegradable balloon spacers designed to protect normal tissue during radiation therapy for cancer. Its flagship product, the ProSpace balloon spacer, has received CE marking and demonstrates superior efficacy and safety in safeguarding the rectum during prostate cancer radiation therapy. By creating a temporary separation between the rectum and targeted tissues, BioProtect's technology significantly reduces the risk of serious and chronic side effects associated with radiation treatment while enhancing tumor control. Additionally, the company's platform of biodegradable implantable balloons addresses a variety of unmet clinical needs in the growing radiotherapy spacers market.

CurvaFix, Inc. is a medical device company based in Bellevue, Washington, founded in 2017. The company specializes in developing innovative solutions for pelvic fracture repair, addressing unmet needs in orthopedic trauma. Its flagship product, The CurvaFix, is an intramedullary rod screw designed to adapt to the natural shape of bones, particularly in the pelvis. This capability allows the device to effectively fill the space within curved bones, facilitating simpler and shorter surgical procedures. By improving surgical outcomes, CurvaFix aims to enhance patient recovery times and overall treatment efficacy.

eXmoor Pharma is a consultancy firm that focuses on technical and strategic solutions in the fields of cell and gene therapies and biopharmaceuticals. The company operates a contract development and manufacturing business tailored for advanced therapy medicinal products (ATMPs). eXmoor Pharma provides a comprehensive suite of services, including manufacturing strategy, process development consultancy, and bioprocess engineering. By collaborating closely with clients, the company assists in designing projects that align with their specific needs and commercial goals, facilitating the advancement of innovative therapeutic solutions.

GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, dedicated to improving the lives of patients with brain tumors. Founded in 2017, the company has developed an innovative treatment approach through its flagship product, GammaTile, which combines a biocompatible, conformable collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a bioresorbable solution that enhances treatment efficacy. GammaTile is protected by multiple patents and has the potential to benefit a significant patient population, with an estimated 176,000 patients diagnosed annually in the United States. To date, clinical trials at Barrow Neurological Institute have demonstrated promising outcomes, with significant clinical improvements observed in patients treated with this novel device.

OSSIO is an orthopedic fixation company established in 2014, dedicated to revolutionizing the orthopedic market by offering a non-permanent alternative to traditional metal implants. The company's flagship product, OSSIOfiber™, is a biocomposite material platform that combines reinforcing mineral fibers with intelligent bone regeneration technology. This innovative solution enables patients' bodies to regrow bone and recover from orthopedic disorders while minimizing inflammation and weakness often associated with other bio-resorbable materials. OSSIO aims to transform the $10 billion+ orthopedic fixation market by providing a more biologically friendly option for both patients and physicians.

Neurolens is a company founded in 2012 and based in Costa Mesa, California, specializing in innovative vision solutions. It develops prescription lenses that incorporate a contoured prism to enhance eye alignment, addressing common issues such as headaches, neck or shoulder pain, and eyestrain that often arise from prolonged use of digital devices, reading, or detailed tasks. Neurolens also offers a vision measurement device system that utilizes an advanced eye-tracking technology to detect even minor misalignments in the eyes. This capability enables effective treatment for patients suffering from chronic headaches and other related symptoms, making Neurolens a key player in the vision correction market.

Nalu Medical is an early-stage company based in Carlsbad, California, focused on developing innovative medical devices to enhance the treatment of chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator that is cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS). Nalu Medical's neurostimulation devices leverage neuromodulation technology to offer a variety of therapeutic options aimed at alleviating chronic pain, thereby improving the quality of life for patients.

VERO Biotech LLC is a biopharmaceutical company focused on developing and commercializing innovative products for patients with pulmonary and cardiac conditions. The company specializes in inhaled nitric oxide (NO) delivery systems, which are designed for both hospital settings and longer-term home use. Utilizing its proprietary GeNOsyl drug delivery technology, VERO Biotech offers a user-friendly solution that includes a single-use drug cassette coupled with a portable console or wearable controller. This technology aims to provide a safe and consistent administration of nitric oxide for various therapeutic applications, addressing unmet medical needs such as pulmonary arterial hypertension and hypoxic respiratory failure in newborns. Founded in 2006 and based in Atlanta, Georgia, VERO Biotech was previously known as GeNO LLC.

Inbrace is a medical device company focused on revolutionizing orthodontic treatment with its innovative device that aligns teeth discreetly behind the teeth. This system utilizes patented self-guiding technology to apply continuous forces, allowing for gentle teeth correction while minimizing discomfort and reducing the frequency of dental visits compared to traditional methods. Inbrace aims to enhance patient confidence and satisfaction by addressing common concerns associated with orthodontic treatment. The company incorporates digital treatment planning, computer modeling, and direct digital manufacturing to provide a scalable, personalized solution that meets the diverse needs of orthodontic patients. With its FDA registration, Inbrace is positioned to disrupt the orthodontics market and drive practice growth for dental clinicians.

eXmoor Pharma is a consultancy firm that focuses on technical and strategic solutions in the fields of cell and gene therapies and biopharmaceuticals. The company operates a contract development and manufacturing business tailored for advanced therapy medicinal products (ATMPs). eXmoor Pharma provides a comprehensive suite of services, including manufacturing strategy, process development consultancy, and bioprocess engineering. By collaborating closely with clients, the company assists in designing projects that align with their specific needs and commercial goals, facilitating the advancement of innovative therapeutic solutions.

GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, dedicated to improving the lives of patients with brain tumors. Founded in 2017, the company has developed an innovative treatment approach through its flagship product, GammaTile, which combines a biocompatible, conformable collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a bioresorbable solution that enhances treatment efficacy. GammaTile is protected by multiple patents and has the potential to benefit a significant patient population, with an estimated 176,000 patients diagnosed annually in the United States. To date, clinical trials at Barrow Neurological Institute have demonstrated promising outcomes, with significant clinical improvements observed in patients treated with this novel device.

Paragon 28, Inc. is a medical device company specializing in products for foot and ankle surgery. Incorporated in 2010 and based in Englewood, Colorado, with an additional headquarters in Dublin, Ireland, the company offers a comprehensive range of surgical solutions, including plates, screws, allograft bone systems, and interference screws for various orthopedic procedures. Its product portfolio features advanced systems such as the PHANTOM Lapidus Intramedullary Nail for arthrodesis correction, the Proximal Rotational Metatarsal Osteotomy for bunion correction, and the Paratrooper Plantar Plate Repair System for plantar plate repairs. Paragon 28 aims to meet the diverse needs of foot and ankle surgeries through its nearly 80 product systems, addressing conditions such as hallux valgus, fracture fixation, and flat foot. The company primarily generates revenue from the United States market.

SkyCell AG is a Swiss company that designs and manufactures temperature-controlled containers specifically for the pharmaceutical industry. Established in 2013 and headquartered in Zurich, SkyCell focuses on providing safe and sustainable shipping solutions for temperature-sensitive goods. Its product lineup includes various models such as SkyCell 2500C, SkyCell 2500CRT, SkyCell 1500C, SkyCell 1500CRT, SkyCell 770C, and SkyCell 770CRT. Each container is equipped with Internet of Things (IoT) sensors that connect to the company's data cloud, allowing for real-time monitoring and intervention to ensure optimal conditions during transport. SkyCell's innovative approach combines hardware, software, and data analytics to enhance supply chain efficiency while minimizing temperature excursions and reducing carbon emissions. The company's software, built on blockchain technology, provides comprehensive visibility of shipments, enabling pharmaceutical companies to manage logistical challenges effectively.

MDxHealth is a molecular diagnostics company focused on developing and commercializing advanced epigenetic tests to assist in the detection and treatment of cancer. The company's product portfolio includes ConfirmMDx, a prostate cancer test aimed at addressing false-negative biopsy concerns; SelectMDx, which guides repeat biopsies for prostate cancer; AssureMDx, a noninvasive liquid biopsy test for bladder cancer; and PredictMDx for Glioblastoma, a tissue methylation test that aids in treatment decisions for brain cancer. Established in 2003 and headquartered in Irvine, California, with additional offices in Belgium and the Netherlands, MDxHealth leverages proprietary genomic and epigenetic technologies to provide actionable diagnostic information. The company's revenue is generated through clinical laboratory services and out-licensing of its patented DNA methylation platform and biomarkers, serving markets primarily in the United States and Europe.

Providence Medical Technology, Inc. is a medical device company specializing in innovative solutions for cervical spine conditions, operating in the United States and internationally. The company has developed a proprietary approach to cervical fusion, offering a range of products designed to treat cervical degenerative disc disease through indirect decompression and fusion. Its product lineup includes the DTRAX Spinal System, which comprises single-use disposable instruments for accessing the spine via posterior surgical incisions; the DTRAX Cervical Cage for treating cervical radiculopathy; the DTRAX Graft, a structural allograft for supporting posterior fusion; and the DTRAX Facet System, a sterile kit containing necessary tools and implants for single-level surgeries. Providence Medical Technology distributes its products through a network of distributors and sales representatives and is headquartered in Lafayette, California.

ZipLine Medical, Inc. is a medical device company that specializes in developing and marketing non-invasive skin closure solutions. Founded in 2007 and based in Campbell, California, the company focuses on its flagship product, the Zip Surgical Skin Closure, which is designed for use across various medical specialties, including cardiology, orthopedics, and emergency medicine. Utilizing its innovative PRELOC technology platform, ZipLine Medical provides a method for rapid skin closure that combines the speed of staples with the aesthetic benefits of sutures, while minimizing the risk of surgical site infections and reducing scar-promoting tension. This technology aims to enhance surgical outcomes by delivering uniform closure forces along incisions, making it applicable to a wide range of surgical procedures. ZipLine Medical operates as a subsidiary of Stryker Corporation.

VitalConnect is a company that specializes in wearable biosensor technology for wireless patient monitoring. It develops innovative solutions that enable continuous monitoring and recording of patients' vital signs through an adhesive patch applied to the body. The technology integrates expertise in biomedical engineering, data analytics, and chip design, allowing vital data to be displayed on mobile devices and computer systems. This capability empowers healthcare professionals to respond promptly to urgent situations and gain valuable insights into patient health, facilitating informed decision-making in both inpatient and outpatient settings, including hospital monitoring, post-discharge care, and cardiac monitoring.

Cheetah Medical, Inc. is a medical technology company specializing in non-invasive solutions for monitoring cardiac output and hemodynamic parameters in critically ill patients. Its flagship product, the NICOM Noninvasive Cardiac Output and Hemodynamic Monitoring System, is designed for clinical applications such as fluid optimization, hemodynamic differential diagnosis, and drug titration. This system provides vital information for conditions like hypovolemic, septic, and cardiogenic shock, as well as aiding in the management of shortness of breath and acute renal failure. The NICOM system is FDA cleared and CE marked, recognized for its substantial equivalence to traditional monitoring systems. Cheetah Medical distributes its products to medical centers across various countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, the company also has offices in Vancouver, Washington, and Tel Aviv, Israel. Cheetah Medical is committed to research and development, partnering closely with clinicians to enhance patient outcomes and improve healthcare efficiency.

Vertos Medical Inc. is a medical device company specializing in minimally invasive treatments for lumbar spinal stenosis, a common spinal condition. Founded in 2005 and headquartered in Aliso Viejo, California, the company develops and markets its mild device, which provides an outpatient treatment option that is fluoroscopically guided and does not require implants. This device encompasses a range of instruments including tissue sculptors, surgical clamps, and bone sculpters, allowing physicians to effectively relieve pressure on the spinal nerves and restore mobility with local anesthesia. Vertos Medical’s innovative approach offers patients a less invasive option compared to traditional lumbar decompression surgeries, making significant advancements in spinal healthcare.

ZipLine Medical, Inc. is a medical device company that specializes in developing and marketing non-invasive skin closure solutions. Founded in 2007 and based in Campbell, California, the company focuses on its flagship product, the Zip Surgical Skin Closure, which is designed for use across various medical specialties, including cardiology, orthopedics, and emergency medicine. Utilizing its innovative PRELOC technology platform, ZipLine Medical provides a method for rapid skin closure that combines the speed of staples with the aesthetic benefits of sutures, while minimizing the risk of surgical site infections and reducing scar-promoting tension. This technology aims to enhance surgical outcomes by delivering uniform closure forces along incisions, making it applicable to a wide range of surgical procedures. ZipLine Medical operates as a subsidiary of Stryker Corporation.

Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

Providence Medical Technology, Inc. is a medical device company specializing in innovative solutions for cervical spine conditions, operating in the United States and internationally. The company has developed a proprietary approach to cervical fusion, offering a range of products designed to treat cervical degenerative disc disease through indirect decompression and fusion. Its product lineup includes the DTRAX Spinal System, which comprises single-use disposable instruments for accessing the spine via posterior surgical incisions; the DTRAX Cervical Cage for treating cervical radiculopathy; the DTRAX Graft, a structural allograft for supporting posterior fusion; and the DTRAX Facet System, a sterile kit containing necessary tools and implants for single-level surgeries. Providence Medical Technology distributes its products through a network of distributors and sales representatives and is headquartered in Lafayette, California.

Biotheranostics, Inc. is a commercial-stage molecular diagnostics company based in San Diego, California, specializing in the discovery, development, and commercialization of proprietary diagnostic, prognostic, and predictive tests aimed at enhancing cancer treatment. The company offers a range of innovative tests, including the Breast Cancer Index, which assists oncologists in making informed decisions regarding extended endocrine therapy for estrogen receptor-positive breast cancer patients. Additionally, CancerTYPE ID provides critical genomic information for the diagnosis and treatment of metastatic cancer, while the bioT3 metastatic cancer solution integrates precise molecular diagnosis with comprehensive biomarker data to improve treatment options for metastatic cancer patients. With a CLIA-certified and CAP-accredited laboratory, Biotheranostics is licensed to perform testing across all 50 states, positioning itself as a leader in addressing unmet medical needs in oncology.

ZipLine Medical, Inc. is a medical device company that specializes in developing and marketing non-invasive skin closure solutions. Founded in 2007 and based in Campbell, California, the company focuses on its flagship product, the Zip Surgical Skin Closure, which is designed for use across various medical specialties, including cardiology, orthopedics, and emergency medicine. Utilizing its innovative PRELOC technology platform, ZipLine Medical provides a method for rapid skin closure that combines the speed of staples with the aesthetic benefits of sutures, while minimizing the risk of surgical site infections and reducing scar-promoting tension. This technology aims to enhance surgical outcomes by delivering uniform closure forces along incisions, making it applicable to a wide range of surgical procedures. ZipLine Medical operates as a subsidiary of Stryker Corporation.

Onbone Oy is a Finnish medical technology company based in Helsinki, specializing in the development and marketing of innovative Woodcast products designed for orthopedic and traumatology applications. The Woodcast product line includes various items such as ribbons, colored splints, folded splints, and heating devices, which are aimed at improving patient care and treatment outcomes. The company distributes its products through local distributors in multiple countries, including Finland, Germany, Sweden, the Netherlands, and Great Britain. Established in 2008, Onbone Oy was previously known as Injectobone Finland Oy before rebranding in January 2010. With a dedicated team of eleven employees, Onbone focuses on providing user-friendly solutions in the medical technology sector.

AmbioPharm, Inc. is a contract manufacturing organization specializing in the production of peptides and biopharmaceuticals for the pharmaceutical and biotech sectors. Founded in 2006 and headquartered in North Augusta, South Carolina, the company operates additional manufacturing facilities in Shanghai, China. AmbioPharm develops a range of products, including peptide active pharmaceutical ingredients (APIs), GLP-grade peptides, custom peptides, and non-peptidic small molecules, addressing the needs of pre-clinical in-vitro, medicinal, and toxicology programs. The company also engages in the production of generic peptide drugs and performs conjugations to proteins and other complex molecules under current Good Manufacturing Practices (cGMP). AmbioPharm's capabilities support various therapeutic areas, including oncology, CNS diseases, and infectious diseases, while its efficient manufacturing processes allow clients to advance their peptide projects from preclinical and clinical stages to commercial readiness at competitive costs.

Vascular Pathways is a privately held medical device company founded by Amir Belson, M.D. The company specializes in the commercialization of the Rapid IntraVascular Start (RIVS) catheter, an FDA-cleared device designed to facilitate rapid, safe, and effective peripheral intravenous (IV) insertion. By focusing on this innovative technology, Vascular Pathways aims to improve patient care and streamline the IV insertion process in clinical settings.

Tarsa Therapeutics, Inc. is a pharmaceutical company focused on developing therapies for the treatment and prevention of osteoporosis and related bone diseases in women, particularly postmenopausal osteoporosis. The company's lead product, TBRIA, is an oral formulation of salmon calcitonin, a peptide hormone designed to slow the rate of bone destruction. Tarsa Therapeutics aims to provide effective treatment options for women who are more than five years post-menopause and for whom alternative therapies may not be suitable. Founded in 2009 and based in Philadelphia, Pennsylvania, the company was previously known as Boneco, Inc.

Wilson Therapeutics, headquartered in Stockholm, Sweden, specializes in developing innovative treatments for rare diseases, primarily focusing on Wilson Disease, a condition caused by excessive copper accumulation. The company's lead product, Decuprate®, is currently undergoing Phase II clinical trials as a potential new therapy for Wilson Disease patients.

Cheetah Medical, Inc. is a medical technology company specializing in non-invasive solutions for monitoring cardiac output and hemodynamic parameters in critically ill patients. Its flagship product, the NICOM Noninvasive Cardiac Output and Hemodynamic Monitoring System, is designed for clinical applications such as fluid optimization, hemodynamic differential diagnosis, and drug titration. This system provides vital information for conditions like hypovolemic, septic, and cardiogenic shock, as well as aiding in the management of shortness of breath and acute renal failure. The NICOM system is FDA cleared and CE marked, recognized for its substantial equivalence to traditional monitoring systems. Cheetah Medical distributes its products to medical centers across various countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, the company also has offices in Vancouver, Washington, and Tel Aviv, Israel. Cheetah Medical is committed to research and development, partnering closely with clinicians to enhance patient outcomes and improve healthcare efficiency.

Horizon Discovery Group plc is a UK-based life science company specializing in gene editing and gene modulation technologies that advance research and clinical applications in human health. Established in 2007 and headquartered in Cambridge, the company designs, manufactures, and applies a wide array of gene editing tools, including custom-made and off-the-shelf RNA interference (RNAi) reagents, CRISPR reagents, and various cell models. Horizon Discovery offers services such as pooled and arrayed CRISPR screens, drug screens, and immunology assays, catering to the needs of academic research labs, biopharmaceutical companies, and contract research organizations. Its extensive product catalog includes over 1,000,000 cell and reagent products that help scientists investigate genetic anomalies associated with diseases like cancer. The company has formed strategic partnerships with various institutions to enhance its offerings, including collaborations for developing innovative gene editing technologies. As of December 2020, Horizon operates as a subsidiary of PerkinElmer (UK) Holdings Ltd.

Cheetah Medical, Inc. is a medical technology company specializing in non-invasive solutions for monitoring cardiac output and hemodynamic parameters in critically ill patients. Its flagship product, the NICOM Noninvasive Cardiac Output and Hemodynamic Monitoring System, is designed for clinical applications such as fluid optimization, hemodynamic differential diagnosis, and drug titration. This system provides vital information for conditions like hypovolemic, septic, and cardiogenic shock, as well as aiding in the management of shortness of breath and acute renal failure. The NICOM system is FDA cleared and CE marked, recognized for its substantial equivalence to traditional monitoring systems. Cheetah Medical distributes its products to medical centers across various countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, the company also has offices in Vancouver, Washington, and Tel Aviv, Israel. Cheetah Medical is committed to research and development, partnering closely with clinicians to enhance patient outcomes and improve healthcare efficiency.

eZono AG is a company based in Jena, Germany, specializing in the design, development, and marketing of tablet ultrasound systems. Founded in 2004, eZono offers a range of products, including the eZono 4000, a system suited for use in operating rooms and critical care areas, and the eZono 3000, a portable ultrasound solution for point-of-care imaging. The company also provides eZGuide, a needle guidance technology that enhances visualization of needle placement, alongside educational Cue Cards that serve as reference materials for various clinical procedures. eZono's products are utilized across multiple medical fields, such as anesthesiology, pain management, emergency medicine, and simulation centers. By empowering non-traditional ultrasound users, eZono aims to improve clinical outcomes, enhance patient satisfaction, and reduce costs associated with ultrasound technology.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Stamford, Connecticut, specializing in the development and commercialization of innovative therapeutics for pain and pruritus. The company primarily focuses on its lead product candidate, CR845 (difelikefalin), which is designed to selectively target kappa opioid receptors and is currently undergoing Phase III clinical trials for treating moderate-to-severe chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Cara is also advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is in trials for pruritus associated with chronic liver disease and atopic dermatitis. Furthermore, the company is developing CR845/difelikefalin Injection for acute postoperative pain, having completed Phase II/III trials. Cara Therapeutics collaborates with Maruishi Pharmaceutical Co., Ltd. and Chong Kun Dang Pharmaceutical Corporation for the development and commercialization of its product candidates in Japan and South Korea, respectively. Founded in 2004, Cara Therapeutics aims to leverage its proprietary drug screening technology to create a pipeline of first-in-class therapeutics.

Tarsa Therapeutics, Inc. is a pharmaceutical company focused on developing therapies for the treatment and prevention of osteoporosis and related bone diseases in women, particularly postmenopausal osteoporosis. The company's lead product, TBRIA, is an oral formulation of salmon calcitonin, a peptide hormone designed to slow the rate of bone destruction. Tarsa Therapeutics aims to provide effective treatment options for women who are more than five years post-menopause and for whom alternative therapies may not be suitable. Founded in 2009 and based in Philadelphia, Pennsylvania, the company was previously known as Boneco, Inc.

Patient Connect is a pioneering company that specializes in delivering evidence-based clinical messages directly at the point of care. The company operates a clinical information platform designed to enhance patient support and education. By providing clinically-driven communications, Patient Connect aims to help patients understand the importance of their medications, ensure proper usage, and address potential side effects and compliance issues. With a strong presence in the healthcare sector, the company has successfully completed over 40 customer projects for a significant number of leading pharmaceutical companies in the UK, establishing itself as a key player in the integration of clinical messaging services within retail and hospital pharmacies.

Horizon Discovery Group plc is a UK-based life science company specializing in gene editing and gene modulation technologies that advance research and clinical applications in human health. Established in 2007 and headquartered in Cambridge, the company designs, manufactures, and applies a wide array of gene editing tools, including custom-made and off-the-shelf RNA interference (RNAi) reagents, CRISPR reagents, and various cell models. Horizon Discovery offers services such as pooled and arrayed CRISPR screens, drug screens, and immunology assays, catering to the needs of academic research labs, biopharmaceutical companies, and contract research organizations. Its extensive product catalog includes over 1,000,000 cell and reagent products that help scientists investigate genetic anomalies associated with diseases like cancer. The company has formed strategic partnerships with various institutions to enhance its offerings, including collaborations for developing innovative gene editing technologies. As of December 2020, Horizon operates as a subsidiary of PerkinElmer (UK) Holdings Ltd.

Beacon Endoscopic is a Boston-based medical device company focused on innovating interventional endoscopic procedures. The company specializes in developing advanced products for upper gastrointestinal and bronchial endoscopy markets, aiming to transform surgical practices through next-generation devices. By enhancing existing procedures and introducing innovative solutions, Beacon Endoscopic seeks to improve patient outcomes and redefine standards in the field of endoscopy.

AccuVein Inc. is a medical device manufacturer specializing in vein visualization technology to assist healthcare professionals in accessing peripheral veins. Founded in 2006 and based in Medford, New York, the company offers a range of portable, non-contact vein finding devices, including its flagship AV400 system. These products enable practitioners to visualize a map of veins on the skin's surface, thereby improving the accuracy and efficiency of procedures such as blood draws, IV infusions, and cosmetic injections. AccuVein's innovative solutions are utilized across various healthcare settings, including surgery centers, long-term care facilities, and imaging centers. The company markets its products through a network of distributors and sales representatives, both domestically and internationally.

Vantia Therapeutics is a pharmaceutical company based in Southampton, United Kingdom, focused on developing novel small molecule drugs to address significant unmet medical needs. Founded in 2008, the company has a strong clinical pipeline that includes VA106483, aimed at treating nocturia, a condition characterized by frequent nighttime urination, and VA111913, designed for dysmenorrhea, which involves painful menstrual cramps. Both drug candidates target conditions that affect millions of individuals and represent substantial market opportunities due to their inadequate existing treatments. Vantia's strategy involves advancing its proprietary drug candidates through Phase II clinical testing and subsequently seeking commercialization partnerships.

Lombard Medical, Inc. is a medical technology company that specializes in developing, manufacturing, and marketing endovascular stent-grafts for the repair of aortic aneurysms. Its principal product, Aorfix, is designed to treat abdominal aortic aneurysms (AAAs) in patients with neck angulations of up to 90 degrees. The company's product portfolio also includes the Altura endovascular stent-graft system for standard AAA anatomies, and advanced delivery systems like Aorflex and IntelliFlex LP, which enhance the precision of stent-graft deployment. Lombard Medical markets its products through a direct sales force and distributors, primarily targeting state- or government-owned hospitals. Established in 2000 and headquartered in Didcot, the United Kingdom, Lombard Medical serves various international markets, with a significant portion of its revenue derived from Japan.

Vascular Pathways is a privately held medical device company founded by Amir Belson, M.D. The company specializes in the commercialization of the Rapid IntraVascular Start (RIVS) catheter, an FDA-cleared device designed to facilitate rapid, safe, and effective peripheral intravenous (IV) insertion. By focusing on this innovative technology, Vascular Pathways aims to improve patient care and streamline the IV insertion process in clinical settings.

SOLX Inc., established in 2000 and based in Waltham, Massachusetts, specializes in developing medical devices for glaucoma treatment. Its primary product is the SOLX Gold Shunt, a minimally invasive device used in glaucoma surgery to manage intraocular pressure (IOP).

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Stamford, Connecticut, specializing in the development and commercialization of innovative therapeutics for pain and pruritus. The company primarily focuses on its lead product candidate, CR845 (difelikefalin), which is designed to selectively target kappa opioid receptors and is currently undergoing Phase III clinical trials for treating moderate-to-severe chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Cara is also advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is in trials for pruritus associated with chronic liver disease and atopic dermatitis. Furthermore, the company is developing CR845/difelikefalin Injection for acute postoperative pain, having completed Phase II/III trials. Cara Therapeutics collaborates with Maruishi Pharmaceutical Co., Ltd. and Chong Kun Dang Pharmaceutical Corporation for the development and commercialization of its product candidates in Japan and South Korea, respectively. Founded in 2004, Cara Therapeutics aims to leverage its proprietary drug screening technology to create a pipeline of first-in-class therapeutics.

Cheetah Medical, Inc. is a medical technology company specializing in non-invasive solutions for monitoring cardiac output and hemodynamic parameters in critically ill patients. Its flagship product, the NICOM Noninvasive Cardiac Output and Hemodynamic Monitoring System, is designed for clinical applications such as fluid optimization, hemodynamic differential diagnosis, and drug titration. This system provides vital information for conditions like hypovolemic, septic, and cardiogenic shock, as well as aiding in the management of shortness of breath and acute renal failure. The NICOM system is FDA cleared and CE marked, recognized for its substantial equivalence to traditional monitoring systems. Cheetah Medical distributes its products to medical centers across various countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, the company also has offices in Vancouver, Washington, and Tel Aviv, Israel. Cheetah Medical is committed to research and development, partnering closely with clinicians to enhance patient outcomes and improve healthcare efficiency.

Tarsa Therapeutics, Inc. is a pharmaceutical company focused on developing therapies for the treatment and prevention of osteoporosis and related bone diseases in women, particularly postmenopausal osteoporosis. The company's lead product, TBRIA, is an oral formulation of salmon calcitonin, a peptide hormone designed to slow the rate of bone destruction. Tarsa Therapeutics aims to provide effective treatment options for women who are more than five years post-menopause and for whom alternative therapies may not be suitable. Founded in 2009 and based in Philadelphia, Pennsylvania, the company was previously known as Boneco, Inc.

Clavis Pharma ASA, a healthcare and clinical-stage pharmaceutical company, engages in the discovery and development of novel small molecule therapeutics for cancer and other unmet medical needs. It also engages in the development of new and improved pharmaceuticals based on its lipid vector technology (LVT). The company has three anti-cancer drugs in clinical development for various indications, and a pipeline of other drug candidates within oncology, virology, and anti-inflammatory diseases. Its products primarily include Elacytarabine, which is in the Phase II clinical trials for various solid tumor indications, as well as in Phase I/II clinical trials for the treatment of blood cancers, including leukemia; Intravenous CP-4126, a multicentre trial open to patients with any type of solid tumours that is in Phase I clinical trials; Oral CP-4126, an analogue of gemcitabine, which is Phase I clinical trial; and CP-4200, an epigenetic modulator that is in preclinical stage for the treatment of hematological malignancies, such as MDS and leukemia. The company�s products also include CP-4010, an analogue of acyclovir that is in the Phase I clinical trial for the treatment of herpes labialis and herpes genitalis; and CP-4018, an analogue of gancyclovir, which is in the preclinical stage. In addition, its products comprise CP-4033, CP-4112, and CP-4114 that are the analogues of ribavirin, betamethason, and prednisolon respectively. The company has a collaboration agreement with Mount Sinai School of Medicine for the design and testing of new LVT based drug candidates for the treatment of cancer and haematological malignancies. Clavis Pharma ASA was founded in 2001 and is headquartered in Oslo, Norway.

BioVex Group is a biotechnology company specializing in the development and commercialization of biological treatments for cancer and infectious diseases. Its primary focus is OncoVEXGM-CSF, an oncolytic vaccine designed to target and destroy cancer cells while preserving surrounding healthy tissues. This innovative therapy utilizes a virus that replicates within solid tumors, leading to their destruction and stimulating a robust systemic immune response against the cancer. OncoVEXGM-CSF has undergone extensive clinical testing with over 110 patients across various solid tumors, including melanoma, head and neck cancer, breast cancer, and pancreatic cancer. The treatment has demonstrated significant efficacy, routinely eliminating tumors at the injection site and resulting in overall disease responses during Phase II trials. Additionally, BioVex is developing ImmunoVEXHSV2, a vaccine aimed at preventing genital herpes, further expanding its portfolio in biologic therapies.

Heptares Therapeutics Ltd. is a clinical-stage drug discovery company based in Welwyn Garden City, United Kingdom, founded in 2007. It specializes in developing novel small-molecule medicines that target G protein-coupled receptors (GPCRs), a significant family of druggable targets associated with various human diseases. Heptares has pioneered a proprietary technology that enables the creation of purified, stabilized, and functional GPCRs, known as StaRs (Stabilised Receptors), which addresses key challenges in the drug development process. The company offers a range of services including GPCR structure-based drug design, X-ray crystallography, surface plasmon resonance, fragment screening, and antibody discovery. Heptares has established strategic partnerships with several organizations, including Pfizer Inc., Kymab Limited, PeptiDream Inc., and Jitsubo Co., Ltd., to enhance its research and development capabilities. As of 2015, Heptares operates as a subsidiary of Sosei Group Corporation.

Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.

PregLem is a Swiss-based specialty biopharmaceutical company focused on developing and commercializing innovative drugs specifically for women's reproductive medicine. The company is dedicated to addressing unmet medical needs in this field, aiming to enhance healthcare options and improve outcomes for women. Through its specialized approach, PregLem seeks to advance the understanding and treatment of conditions related to female reproductive health, positioning itself as a key player in the biopharmaceutical industry.

Heptares Therapeutics Ltd. is a clinical-stage drug discovery company based in Welwyn Garden City, United Kingdom, founded in 2007. It specializes in developing novel small-molecule medicines that target G protein-coupled receptors (GPCRs), a significant family of druggable targets associated with various human diseases. Heptares has pioneered a proprietary technology that enables the creation of purified, stabilized, and functional GPCRs, known as StaRs (Stabilised Receptors), which addresses key challenges in the drug development process. The company offers a range of services including GPCR structure-based drug design, X-ray crystallography, surface plasmon resonance, fragment screening, and antibody discovery. Heptares has established strategic partnerships with several organizations, including Pfizer Inc., Kymab Limited, PeptiDream Inc., and Jitsubo Co., Ltd., to enhance its research and development capabilities. As of 2015, Heptares operates as a subsidiary of Sosei Group Corporation.

Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.

PregLem is a Swiss-based specialty biopharmaceutical company focused on developing and commercializing innovative drugs specifically for women's reproductive medicine. The company is dedicated to addressing unmet medical needs in this field, aiming to enhance healthcare options and improve outcomes for women. Through its specialized approach, PregLem seeks to advance the understanding and treatment of conditions related to female reproductive health, positioning itself as a key player in the biopharmaceutical industry.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Stamford, Connecticut, specializing in the development and commercialization of innovative therapeutics for pain and pruritus. The company primarily focuses on its lead product candidate, CR845 (difelikefalin), which is designed to selectively target kappa opioid receptors and is currently undergoing Phase III clinical trials for treating moderate-to-severe chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Cara is also advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is in trials for pruritus associated with chronic liver disease and atopic dermatitis. Furthermore, the company is developing CR845/difelikefalin Injection for acute postoperative pain, having completed Phase II/III trials. Cara Therapeutics collaborates with Maruishi Pharmaceutical Co., Ltd. and Chong Kun Dang Pharmaceutical Corporation for the development and commercialization of its product candidates in Japan and South Korea, respectively. Founded in 2004, Cara Therapeutics aims to leverage its proprietary drug screening technology to create a pipeline of first-in-class therapeutics.

Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for cardiovascular and metabolic diseases. Headquartered in Bridgewater, New Jersey, Aegerion specializes in therapies for hyperlipidemia, aiming to address high levels of fat particles in the blood. The company's notable product, lomitapide, is a small molecule drug that acts as a microsomal triglyceride transfer protein inhibitor, designed to lower serum lipids, including cholesterol and triglycerides. Aegerion's efforts are directed towards treating conditions such as atherosclerosis, dyslipidemia, obesity, and pancreatitis, thereby enabling healthcare professionals to effectively manage debilitating diseases associated with these metabolic disorders. The company was incorporated in 2005.

BioXell was founded in 2002 as a spinout of Roche Milano Ricerche, a leading biomedical research institute created ten years earlier that focused on chronic inflammatory disease and autoimmunity. The idea to create BioXell originated with Francesco Sinigaglia, founder and director of the Milan-based research institute, following a scientific career path that took him to the University College in London, the Basel Institute of Immunology and the Hoffmann-La Roche research units in Basel. Dr. Sinigaglia, former CEO, approached Roche with his challenging project and a year later BioXell was spun off, with $22m invested by MPM Capital, Index Ventures and Life Science Partners.

Astrodyne TDI Corporation specializes in the development and manufacturing of advanced power solutions. The company offers a wide range of products, including AC/DC power supplies, DC/DC converters, LED drivers, medical power supplies, and EMI/EMC/RFI filters, tailored for diverse applications in industrial, medical, aerospace, military, and semiconductor markets. Founded in 1994 and based in Mansfield, Massachusetts, Astrodyne TDI also operates manufacturing facilities in Elizabeth, New Jersey, and Shanghai, China, along with product design centers in Fremont, California, Elizabeth, New Jersey, and Taipei, Taiwan. The company, previously known as Astrodyne Corporation until its name change in 2015, is committed to delivering innovative power technologies that meet the specific needs of its clients globally.

Spherics develops proprietary bioadhesive encapsulation technologies to improve the oral absorption of small molecule drugs.

BioXell was founded in 2002 as a spinout of Roche Milano Ricerche, a leading biomedical research institute created ten years earlier that focused on chronic inflammatory disease and autoimmunity. The idea to create BioXell originated with Francesco Sinigaglia, founder and director of the Milan-based research institute, following a scientific career path that took him to the University College in London, the Basel Institute of Immunology and the Hoffmann-La Roche research units in Basel. Dr. Sinigaglia, former CEO, approached Roche with his challenging project and a year later BioXell was spun off, with $22m invested by MPM Capital, Index Ventures and Life Science Partners.

Evotec Neurosciences GmbH is a biotechnology company focused on the discovery and development of small molecule drugs aimed at treating Alzheimer's disease and other neurological disorders. The company utilizes innovative approaches to develop therapeutics that address significant unmet medical needs in the field of neuroscience. By leveraging advanced scientific techniques and expertise, Evotec Neurosciences aims to contribute to the advancement of treatments for complex neurological conditions.

Momenta Pharmaceuticals, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, that focuses on the discovery and development of innovative therapeutics for rare immune-mediated diseases. The company's product pipeline includes novel therapeutics such as M281, a fully-human monoclonal antibody targeting the neonatal Fc receptor to reduce circulating IgG antibodies; M254, aimed at treating inflammatory diseases; and M230, a recombinant trivalent IgG1 Fc multimer designed for enhanced therapeutic activity. Additionally, Momenta has developed complex generic products, including M-Enoxaparin, a generic version of Lovenox, and M356, a generic of Copaxone for multiple sclerosis. Momenta also has biosimilar programs, including M923, a biosimilar of HUMIRA, and M710, a biosimilar of EYLEA for various eye conditions. Despite previously pursuing the generics and biosimilars market, the company shifted its focus to innovative drug development, with several promising candidates in the pipeline for autoimmune diseases. Momenta was founded in 2001 and operates as a subsidiary of Johnson & Johnson.

Xention Limited is a biopharmaceutical company based in Cambridge, United Kingdom, established in 2002. The company focuses on the discovery and development of innovative ion channel-modulating drugs aimed at addressing significant medical needs. Xention specializes in creating therapies for conditions such as atrial fibrillation, overactive bladder, pain, and autoimmune diseases. By developing drug candidates that target two novel, well-characterized ion channels, Xention seeks to offer breakthrough treatments that enhance current therapeutic options in these areas.

Momenta Pharmaceuticals, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, that focuses on the discovery and development of innovative therapeutics for rare immune-mediated diseases. The company's product pipeline includes novel therapeutics such as M281, a fully-human monoclonal antibody targeting the neonatal Fc receptor to reduce circulating IgG antibodies; M254, aimed at treating inflammatory diseases; and M230, a recombinant trivalent IgG1 Fc multimer designed for enhanced therapeutic activity. Additionally, Momenta has developed complex generic products, including M-Enoxaparin, a generic version of Lovenox, and M356, a generic of Copaxone for multiple sclerosis. Momenta also has biosimilar programs, including M923, a biosimilar of HUMIRA, and M710, a biosimilar of EYLEA for various eye conditions. Despite previously pursuing the generics and biosimilars market, the company shifted its focus to innovative drug development, with several promising candidates in the pipeline for autoimmune diseases. Momenta was founded in 2001 and operates as a subsidiary of Johnson & Johnson.

Oxxon Therapeutics™ (Oxxon) is a company developing the next generation of innovative antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. To date, the company has built an initial pipeline through its patented Hi-8™ PrimeBoost immunotherapy platform, an approach that allows the rapid development of products to selectively stimulate and enhance potent immune responses against disease. The company has successfully completed phase II clinical programmes in melanoma and hepatitis B and has a third development programme underway in HIV. In addition, the company intends to leverage its enabling platform through partnerships with companies developing therapeutic and preventative vaccine products.

Avantium is a Dutch technology company specializing in advanced high-throughput research and development for energy, chemicals, and pharmaceutical industries. Headquartered in Amsterdam with state-of-the-art laboratories, Avantium's proprietary technology accelerates product and process innovation while reducing costs. With over 70 global clients, including industry leaders, Avantium has proven its technology's validity and commercial viability. The company focuses on developing new biofuels, bio-based chemicals, and novel crystal forms of marketed drugs under patent. Its team comprises highly educated professionals in catalysis, crystallography, organic chemistry, engineering, statistics, cheminformatics, and software development, collaborating closely with partner R&D organizations to drive innovation.

BioXell was founded in 2002 as a spinout of Roche Milano Ricerche, a leading biomedical research institute created ten years earlier that focused on chronic inflammatory disease and autoimmunity. The idea to create BioXell originated with Francesco Sinigaglia, founder and director of the Milan-based research institute, following a scientific career path that took him to the University College in London, the Basel Institute of Immunology and the Hoffmann-La Roche research units in Basel. Dr. Sinigaglia, former CEO, approached Roche with his challenging project and a year later BioXell was spun off, with $22m invested by MPM Capital, Index Ventures and Life Science Partners.

De Novo Pharmaceuticals is an emerging computational drug design company. De Novo Pharmaceuticals uses its proprietary computational software for drug design to create novel, patentable lead molecules as candidates for drug development. De Novo's proprietary algorithms can convert information from structural genomics and medicinal chemistry rapidly into new chemical designs, maximising value within a pharmaceutical partner's research portfolio. De Novo's drug discovery partners include British Biotechnology, Aventis Pharmaceuticals and NV Organon.